Concord Biotech Share Price in Focus; USFDA Inspection at Unit II Valthera Facility Concludes with Minor Observation

Concord Biotech’s Unit II formulation facility at Valthera, Ahmedabad, has completed an inspection by the US Food and Drug Administration (USFDA). The inspection concluded on September 18, 2026, as per the exchange filing. 

The USFDA issued one minor observation at the end of the inspection. Concord Biotech said the observation was procedural in nature and not related to GMP.  

USFDA Inspection Concludes at Valthera 

The inspection was carried out at the company’s Unit II formulation facility in Valthera, Dholka, Ahmedabad. Concord Biotech will submit a comprehensive response to the observation within the stipulated timeline.  

The company’s Valthera facility is located at Unit II-297-298/2p in Dholka, Ahmedabad, Gujarat.  

Company Expects Operations to Continue 

Concord Biotech said it does not expect the development to have any material impact on its current business operations or existing supplies from the facility.  

The company will provide its response to the observation within the stipulated timeline following the completion of the USFDA inspection.  

Read More: HCLTech Share Price in Focus; Board to Consider Q2FY27 Results on October 12, 2026! 

Concord Biotech Share Price Performance  

As of 18 September 2026, at 12:54 PM, Concord Biotech share price was trading at ₹1,486 per share, reflecting a surge of 1.70% from the previous trading session. 

Conclusion 

The USFDA inspection at Concord Biotech’s Unit II Valthera formulation facility has concluded with one minor procedural observation. The company expects no material impact on its current operations or existing supplies from the facility.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.